Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors
Status:
Completed
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase I, multi-center study of GM-CT-01, which has been shown to increase the
anti-tumor activity of 5-fluorouracil in mice. The primary reason for doing the study is to
determine the safety of GM-CT-01 given alone and in combination with therapeutical dosage of
5-Fluorouracil, in patients who have advanced cancer that can be measured by CT scan.